Exploring the inhibition mechanism on HIF-2 by inhibitor PT2399 and 0X3 using molecular dynamics simulations

Area of Science:

• Oncology
• Molecular Biology
• Biophysics

Background:

• Clear cell renal cell carcinoma (ccRCC) therapy increasingly targets hypoxia-inducible factor 2 (HIF-2).
• PT2399 and 0X3 are identified as promising HIF-2 inhibitors, but their precise inhibition mechanisms remain unclear.
• Understanding these mechanisms is crucial for developing effective ccRCC treatments.

Purpose of the Study:

• To elucidate the molecular mechanisms by which PT2399 and 0X3 inhibit HIF-2 heterodimerization.
• To investigate the structural impact of these inhibitors on HIF-2 at an atomic level.
• To compare the efficacy of PT2399 and 0X3 based on their interaction with HIF-2.

Main Methods:

• Molecular dynamics (MD) simulations were employed to analyze the dynamic behavior of HIF-2.
• Molecular docking was used to predict the binding modes and interactions of PT2399 and 0X3 with HIF-2.
• Analysis focused on structural motifs, interdomain interactions, and conformational changes.

Main Results:

• Inhibitor binding disrupts critical hydrogen bonds and hydrophobic interactions within the HIF-2 heterodimer.
• Local conformational changes at the binding interface are sufficient to disrupt heterodimerization.
• PT2399, with its diverse substituents, demonstrated superior inhibitory potential over 0X3 due to enhanced hydrogen bonding and greater structural perturbation.

Conclusions:

• The study provides atomic-level insights into how PT2399 and 0X3 inhibit HIF-2 heterodimerization.
• Disruption of interdomain interactions via targeted residue perturbation is a viable inhibition strategy.
• PT2399's chemical structure facilitates stronger interactions, making it a more promising candidate for ccRCC drug development.